rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Farnesyltransferase inhibitors in cancer therapy
  name:
    name part: Sebti, Saïd M.
  name:
    name part: Hamilton, Andrew D.
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  genre: bibliography
  genre: Electronic books.
  origin info:
    place:
      place term: nju
    date issued: 2001
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: remote
    extent: 1 online resource (xii, 280 pages) : illustrations
  abstract: With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer-causing activity. In Farnesyltransferase Inhibitors in Cancer Therapy, cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase inhibitors (GGTIs) that can be used as anticancer drugs and in cardiovascular and parasitic therapy. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. The book also discusses the results from several phase I and II human clinical trials using a variety of FTIs, and demonstrates the design of hypothesis-driven clinical trials with proof-of-concept using biochemical endpoints. Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors.
  note: edited by Said M. Sebti and Andrew Hamilton.
  note: Electronic resource.
  note: Includes bibliographical references and index.
  subject:
    topic: Dimethylallyltranstransferase
    topic: Inhibitors
    topic: Therapeutic use
    topic: Testing
  subject:
    topic: Cancer
    topic: Chemotherapy
  subject:
    topic: Dimethylallyltranstransferase
    topic: antagonists & inhibitors
  subject:
    topic: Antineoplastic Agents
    topic: chemical synthesis
  subject:
    topic: Drug Design
  subject:
    topic: Enzyme Inhibitors
    topic: therapeutic use
  subject:
    topic: Genes, ras
  subject:
    topic: MEDICAL
    topic: Oncology
  subject:
    topic: HEALTH & FITNESS
    topic: Diseases
    topic: Cancer
  classification: RC271.D534 F37 2001eb
  classification: 616.99/4061
  classification: 2001 F-732
  classification: QU 141 F235 2001
  related item:
    title info:
      title: Farnesyltransferase inhibitors in cancer therapy
    origin info:
      publisher: Totowa, N.J. : Humana Press, c2001
    identifier: (DLC) 00035038
    identifier: (OCoLC)43701932
  related item:
    title info:
      title: Cancer drug discovery and development
  identifier: 9781592590131 (electronic bk.)
  identifier: 1592590136 (electronic bk.)
  identifier: 0896036294 (alk. paper)
  identifier: 9780896036291 (alk. paper)
  identifier: http://proxy.library.tamu.edu/login
  record info:
    record content source: N$T
    record creation date: 070910
    record change date: 20260422154309.5
    record identifier: in00003510207
    language of cataloging:
      language term: eng